Edna Chow Maneval

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509

James D. Joseph, Nhin Lu, Jing Qian et al. · Cancer Discovery · 2013 · 581 citations · Full text

Medicine, Oncology, Pharmacology +17

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Alexander Drilon, G. Li, Snjezana Doğan et al. · Annals of Oncology · 2016 · 302 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer

Dana E. Rathkopf, Michael J. Morris, Josef J. Fox et al. · Journal of Clinical Oncology · 2013 · 264 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Bernard Escudier, Jan Roigas, Silke Gillessen et al. · Journal of Clinical Oncology · 2009 · 208 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

M. Dror Michaelson, Stéphane Oudard, Yen-Chuan Ou et al. · Journal of Clinical Oncology · 2013 · 190 citations

Medicine, Oncology, Pharmacology +14